With no internal pharmacovigilance resources in place, the company required a drug safety framework capable of supporting safety data collection, evaluation, and reporting throughout the clinical development process. Qinecsa partnered with the client to create a practical, compliant foundation designed to support both immediate trial requirements and future growth.

The Challenge

The client was preparing for clinical trials but lacked the internal pharmacovigilance expertise needed to establish and maintain a compliant drug safety system. Regulatory requirements dictated that an appropriate safety framework be in place before any patient exposure could occur.

Although forecasted serious adverse event (SAE) volumes were expected to be low due to the nature of the compounds and patient population, the company still needed a robust approach to safety data collection, evaluation, and dissemination. In addition, the organization required an experienced European pharmacovigilance partner to support all aspects of drug safety during clinical development.

Qinecsa’s Approach

Qinecsa delivered a tailored solution focused on establishing a compliant and scalable drug safety framework aligned with applicable regulatory requirements. This engagement is particularly relevant to Qinecsa’s Pharmacovigilance Consulting, Drug Safety Services, and Clinical Trial Pharmacovigilance capabilities.

Establishing a Compliant Safety Framework

A streamlined pharmacovigilance framework was developed, including the policies and procedures required to support the collection, evaluation, and dissemination of serious adverse events. The framework was designed to meet relevant legislative requirements while remaining practical for a developing biotechnology organization.

Training and Knowledge Management

To support ongoing compliance, all client employees received training on drug safety policies and regulatory obligations. Qinecsa also implemented a structured approach to compound knowledge management, ensuring that emerging safety information was documented and maintained consistently as the product’s safety profile evolved throughout development.

The Outcome

The implemented framework enabled the client to meet the regulatory requirements necessary to support first-in-man exposure within the expected timelines. Beyond addressing immediate clinical development needs, the solution provided a foundation for future planning by supporting longer-term budget and resource strategies.

The client subsequently navigated regulatory inspections successfully and benefited from a well-maintained knowledge management process that supported the seamless creation of development Risk Management Plans (RMPs).